Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our Twin Momentum Investor model based on the published strategy ...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

Abbott stock fell more than 7% in premarket trading after the company missed on Q4 revenue and gave a weaker Q1 2026 outlook, ...

Abbott Laboratories (NYSE:ABT) has greatly exceeded the broader S&P 500 index this year, with its stock price increasing by 18% compared to the S&P 500’s 6% rise. This strong performance is due to the ...

Abbott Laboratories ABT reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.50, which came in line with the ...

Abbott (ABT) came out with quarterly earnings of $1.5 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $1.34 per share a year ago. These figures are adjusted for non ...

Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter and narrowed fiscal 2025 guidance on Wednesday. The company reported third-quarter sales of $11.37 billion, slightly missing ...

Stock index futures seesawed on Thursday, a day after Wall Street closed in the green after President Donald Trump denied reports of planning to fire Federal Reserve Chair Jerome Powell. Here are four ...